Antimetabolite interactions with epidermal growth factor

Related Experiment Video

Updated: Oct 12, 2026

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

E A Kopecky1, D S Rootman

  • 1Department of Ophthalmology, University of Toronto, Toronto Hospital, Ontario.

Current Eye Research
|March 1, 1996
PubMed

Insights

Antimetabolites like 5-fluorouracil (5FU) and mitomycin C (MMC) impact corneal healing. Epidermal growth factor (EGF) did not improve healing delayed by these antimetabolites, suggesting limited therapeutic use.

Area of Science:

  • Ophthalmology
  • Wound Healing
  • Pharmacology

Background:

  • Antimetabolites, including 5-fluorouracil (5FU) and mitomycin C (MMC), are known to impede wound healing processes.
  • Epidermal growth factor (EGF) has demonstrated efficacy in accelerating corneal epithelial wound healing.

Purpose of the Study:

  • To investigate the impact of Epidermal Growth Factor (EGF) on corneal epithelial wound healing previously affected by antimetabolite treatments.
  • To evaluate the efficacy of EGF in counteracting the delayed wound healing caused by 5FU and MMC.

Main Methods:

  • New Zealand White rabbits received subconjunctival 5FU or topical MMC, alongside saline controls.
  • Anterior stromal wounds were created and perfused with saline or EGF (50 µg/ml) for 6 hours.
  • Wound healing was quantitatively assessed via morphometry over a 6-day period.

Main Results:

  • Topical MMC significantly delayed corneal wound healing compared to controls (P < 0.05); subconjunctival 5FU did not (P > 0.05).
  • MMC significantly delayed healing more than 5FU, irrespective of saline or EGF perfusion.
  • EGF perfusion did not significantly alter corneal wound healing rates in the presence of either 5FU or MMC (P > 0.05).

Conclusions:

  • Subconjunctival 5FU does not affect corneal wound healing, while topical MMC significantly delays it.
  • EGF treatment failed to overcome the inhibitory effects of MMC on corneal wound healing.
  • EGF therapy may not be beneficial for treating complications arising from antimetabolite use in corneal healing.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Studying TGF-&#946; Signaling and TGF-&#946;-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own EpiSCs...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...